Raymond James & Associates Virios Therapeutics, Inc. Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Virios Therapeutics, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 30,600 shares of VIRI stock, worth $135,864. This represents 0.0% of its overall portfolio holdings.
Number of Shares
30,600
Previous 30,000
2.0%
Holding current value
$135,864
Previous $6,000
16.67%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding VIRI
# of Institutions
28Shares Held
1.12MCall Options Held
0Put Options Held
0-
Geode Capital Management, LLC Boston, MA231KShares$1.02 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA209KShares$927,4400.0% of portfolio
-
Ubs Group Ag186KShares$826,1150.0% of portfolio
-
Hrt Financial LP New York, NY81.6KShares$362,1880.0% of portfolio
-
Two Sigma Securities, LLC New York, NY53.4KShares$237,0600.0% of portfolio
About Virios Therapeutics, Inc.
- Ticker VIRI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,330,400
- Market Cap $81.4M
- Description
- Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC...